Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

34.07
-0.0900-0.26%
Post-market: 34.00-0.0696-0.20%18:56 EDT
Volume:2.71M
Turnover:92.68M
Market Cap:39.69B
PE:25.44
High:34.85
Open:34.29
Low:34.02
Close:34.16
52wk High:37.35
52wk Low:14.99
Shares:1.17B
Float Shares:1.14B
Volume Ratio:0.53
T/O Rate:0.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.34
EPS(LYR):1.21
ROE:21.60%
ROA:6.38%
PB:4.82
PE(LYR):28.16

Loading ...

Teva Pharmaceuticals Exec Says It Is Difficult to Predict Whether There Will Be a Channel Drawdown Ahead of Price Changes Set to Take Effect in 2027

THOMSON REUTERS
·
Apr 29

Teva Pharmaceuticals Exec Says Co Is Seeing Nominal Increases in Some Transportation and Energy Costs Related to Middle East Conflict

THOMSON REUTERS
·
Apr 29

Teva Pharmaceuticals Exec Says Co Continue to Monitor Geopolitical Situation in the Middle East - Conf Call

THOMSON REUTERS
·
Apr 29

Teva reports Q1 EPS 53c, consensus 46c

TIPRANKS
·
Apr 29

Teva Pharmaceutical Beats First-Quarter Profit Estimates On Branded Drugs Demand

Reuters
·
Apr 29

GUIDANCE: (TEVA) Teva Pharmaceutical Industries Expects 2026 Non-GAAP EPS Range $1.91 - 2.11

MT Newswires Live
·
Apr 29

Stock Track | Teva Pharmaceutical Soars 5.41% in Pre-Market on Strong Q1 Earnings Beat and Emalex Acquisition

Stock Track
·
Apr 29

Teva Pharmaceutical Indus Q1 Adj. EPS $0.53 Beats $0.48 Estimate, Sales $3.982B Beat $3.810B Estimate

Benzinga
·
Apr 29

Press Release: Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Dow Jones
·
Apr 29

Teva to acquire Emalex Biosciences for $700M at closing

TIPRANKS
·
Apr 29

Notable companies reporting before tomorrow’s open

TIPRANKS
·
Apr 29

Teva put volume heavy and directionally bearish

TIPRANKS
·
Apr 29

Teva’s Home Ground Schizophrenia Push And What It Could Mean For Investors

Simply Wall St.
·
Apr 28

Teva Pharmaceutical Industries Ltd expected to post earnings of 46 cents a share - Earnings Preview

Reuters
·
Apr 27

Earning Preview: Teva Pharmaceutical this quarter’s revenue is expected to decrease by 4.49%, and institutional views are bullish

Earnings Agent
·
Apr 23

Teva put volume heavy and directionally bearish

TIPRANKS
·
Apr 21

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After The Home Ground Schizophrenia Platform Launch

Simply Wall St.
·
Apr 19

US appeals court revives Teva lawsuit against Eli Lilly over migraine drug

Reuters
·
Apr 16

Does Biosimilar Wins in Osteoporosis and Allergy Care Change The Bull Case For Teva (TEVA)?

Simply Wall St.
·
Apr 13

Teva Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
Apr 10